Porcine Xenotransplantation in End-Stage Kidney Disease
Sep 4, 2025DOI: 10.1056/nejmc2508235CorrespondenceNEJM
To the Editor: Kawai et al. (May 15 issue) report a gene-edited porcine kidney xenograft in a human participant who survived for 52 days, an outcome that represents a landmark achievement in the field of xenotransplantation. Despite this progress toward improving the survival of xenografts, challenges remain. Although CD46 and CD55 expression probably mitigated complement-mediated injury in the patient described by Kawai et al., we propose a dual-targeting approach to further reduce xenograft rejection. First, CRISPR-mediated claudin-2 knockout (combined with CD46 and CD55 transgenes) might reduce membrane attack complex (MAC) deposition. Li et al. showed that claudin-2 promotes C5b-9 assembly . . .